文献速递免疫规划慢病防控与筛查

澳大利亚HPV疫苗接种项目实施9-12年后女性HPV感染率及危险因素

Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
PubMed 文献 · Vaccine · 2021-07-17

本研究评估澳大利亚四价HPV疫苗接种项目实施9-12年后18-35岁女性HPV感染的危险因素。在1564名女性中,疫苗靶向型HPV总感染率为2.0%(95%CI:1.4-2.8%),仅受疫苗接种状态影响;未接种女性感染率为5.5%,接种女性为0.7%(aOR=0.13, 95%CI:0.05-0.30)。接种女性HPV31/33/45感染率亦较低(4% vs 7%,aOR=0.51, 95%CI:0.29-0.89),提示交叉保护。

要点

  • 疫苗接种者四价HPV疫苗靶向型感染率显著低于未接种者(0.7% vs 5.5%)
  • 非疫苗靶向型HPV感染率40.4%,受年龄和性伴数影响,与接种状态无关
  • 接种女性HPV31/33/45感染率较低,提示四价疫苗存在交叉保护

核心结论

  • 疫苗接种显著降低了澳大利亚女性疫苗靶向型HPV感染率,包括具有已知感染危险因素的女性。
  • 接种女性对HPV31/33/45型获得适度交叉保护,结果强化了HPV疫苗接种的重要性。

研究设计与样本

  • 2015-2018年招募18-35岁就诊女性,自采阴道标本进行HPV基因分型(Roche Linear Array)并完成问卷。
  • 疫苗接种状态经国家登记处核实,计算调整比值比(aOR)及95%置信区间。

主要发现

  • 1564名女性(中位年龄24岁,IQR 21-27岁)中,登记确认至少1剂疫苗接种率在18-21岁和22-24岁组最高,分别为69.3%和68.1%,30-35岁组降至42.9%。
  • 四价疫苗靶向型HPV总感染率为2.0%(95%CI:1.4-2.8%),未接种女性为5.5%,接种女性为0.7%(aOR=0.13, 95%CI:0.05-0.30)。
  • 其余HPV型别感染率为40.4%(95%CI:38.0-42.9%),受年轻年龄组(p-trend<0.001)、更近的性伴数(p<0.001)和终生性伴数(p-trend<0.001)影响,与疫苗接种状态无关。
  • HPV31/33/45感染率在接种女性中为4%,未接种女性为7%(aOR=0.51, 95%CI:0.29-0.89),提示交叉保护。

临床怎么用

  • 应继续推进HPV疫苗接种以维持疫苗靶向型HPV感染的低流行状态。
  • 对未接种女性,尤其具有年龄和性伴数等危险因素者,应加强HPV感染筛查与健康教育。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Australia, high and widespread uptake of the quadrivalent human papillomavirus (HPV) vaccine has led to substantial population-level reductions in the prevalence of quadrivalent vaccine targeted HPV genotypes 6/11/16/18 in women aged ≤ 35 years. We assessed risk factors for HPV detection among 18-35 year old women, 9-12 years after vaccine program introduction. METHODS: Women attending health services between 2015 and 2018 provided a self-collected vaginal specimen for HPV genotyping (Roche Linear Array) and completed a questionnaire. HPV vaccination status was validated against the National Register. Adjusted odds ratios (aORs) and 95% confidence intervals (CI) were calculated for factors associated with HPV detection. RESULTS: Among 1564 women (median age 24 years; IQR 21-27 years), Register-confirmed ≥ 1-dose vaccine coverage was highest at 69.3% and 68.1% among women aged 18-21 and 22-24 years respectively, decreasing to 42.9% among those aged 30-35 years. Overall prevalence of quadrivalent vaccine-targeted HPV types was very low (2.0%; 95% CI: 1.4-2.8%) and influenced only by vaccination status (5.5% among unvaccinated compared with 0.7% among vaccinated women; aOR = 0.13 (95% CI: 0.05-0.30)). Prevalence of remaining HPV types, at 40.4% (95% CI: 38.0-42.9%), was influenced by established risk factors for HPV infection; younger age-group (p-trend < 0.001), more recent (p < 0.001) and lifetime sexual partners (p-trend < 0.001), but not vaccination status. Prevalence of HPV31/33/45, which shared risk factors with that of non-vaccine targeted HPV types, was also lower among vaccinated (4%) compared with unvaccinated (7%) women (aOR = 0.51; 95% CI: 0.29-0.89), indicative of cross-protection. CONCLUSION: Vaccination has changed the epidemiology of HPV infection in Australian women, having markedly reduced the prevalence of vaccine-targeted types, including amongst women with known risk factors for infection. Vaccinated women appear to be benefiting from modest cross-protection against types 31/33/45 afforded by the quadrivalent HPV vaccine. These results reinforce the importance of HPV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shilling H, Garland SM, Atchison S, et al. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction. Vaccine. 2021. PMID: 34281743. doi:10.1016/j.vaccine.2021.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。